Status and phase
Conditions
Treatments
About
The investigators focused on patients with refractory acute leukemia or MDS and designed a phase 1 trial of escalated cladribine doses in the Cla-Flu-Bu RTC regimen using PK-guided myeloablative busulfan doses. This scheme allows combining different optimization of RTC experienced over years (Flu-Bu RTC, PK-guided myeloablative busulfan doses, a second purine analog cladribine) to approach a specific platform to treat refractory diseases.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
29 participants in 1 patient group
Loading...
Central trial contact
Dominique Genre, MD; Jihane Pakradouni, PharmD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal